Dose-Response Relationship, Drug

"Dose-Response Relationship, Drug" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The relationship between the dose of an administered drug and the response of the organism to the drug.

Descriptor ID	D004305
MeSH Number(s)	G07.690.773.875 G07.690.936.500
Concept/Terms	Dose-Response Relationship, Drug Dose-Response Relationship, Drug Dose-Response Relationships, Drug Drug Dose-Response Relationship Drug Dose-Response Relationships Relationship, Drug Dose-Response Relationships, Drug Dose-Response Dose Response Relationship, Drug

Below are MeSH descriptors whose meaning is more general than "Dose-Response Relationship, Drug".

Biological Sciences [G]
Physiological Phenomena [G07]
Pharmacological and Toxicological Phenomena [G07.690]
Pharmacological Phenomena [G07.690.773]
Dose-Response Relationship, Drug [G07.690.773.875]
Toxicological Phenomena [G07.690.936]
Dose-Response Relationship, Drug [G07.690.936.500]

Below are MeSH descriptors whose meaning is related to "Dose-Response Relationship, Drug".

Below are MeSH descriptors whose meaning is more specific than "Dose-Response Relationship, Drug".

Dose-Response Relationship, Drug
Hormesis
Lethal Dose 50

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Dose-Response Relationship, Drug" by people in this website by year, and whether "Dose-Response Relationship, Drug" was a major or minor topic of these publications.

Bar chart showing 668 publications over 29 distinct years, with a maximum of 48 publications in 2005

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	0	8	8
1996	0	13	13
1997	0	9	9
1998	0	15	15
1999	0	11	11
2000	0	9	9
2001	0	15	15
2002	0	34	34
2003	0	35	35
2004	0	34	34
2005	0	48	48
2006	1	41	42
2007	0	34	34
2008	1	37	38
2009	0	33	33
2010	0	31	31
2011	0	32	32
2012	0	31	31
2013	0	23	23
2014	0	28	28
2015	0	25	25
2016	1	31	32
2017	1	19	20
2018	0	21	21
2019	0	19	19
2020	0	11	11
2021	0	7	7
2024	1	8	9
2025	0	1	1

Below are the most recent publications written about "Dose-Response Relationship, Drug" by people in Profiles.

Banerjee R, Sexton R, Cowan AJ, Rosenberg AS, Ailawadhi S, Rajkumar SV, Kumar S, Dispenzieri A, Lonial S, Durie BGM, Richardson PG, Usmani SZ, Hoering A, Orlowski RZ. Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis. Blood. 2025 Jan 02; 145(1):75-84.

View in: PubMed
Bisht P, Bhattacharya A, Pal A, Singh R, Verma SK. Design and synthesis of novel 3,7-dihydro-1H-purine-2,6-diones as DPP-4 inhibitors: An in silico, in vitro and in vivo approach. Eur J Med Chem. 2025 Feb 05; 283:117160.

View in: PubMed
Zhao X, Di J, Luo D, Verma R, Verma SK, Verma S, Ravindar L, Koshle A, Dewangan HK, Gupta R, Chandra S, Deshpande S, Vaishnav Y, Rakesh KP. Thiazole - A promising scaffold for antituberculosis agents and structure-activity relationships studies. Bioorg Chem. 2025 Jan; 154:108035.

View in: PubMed
Cleveland NK, Ghosh S, Kathe N, Umashankar K, Mirchandani K, Hait A, Paul R, Candela N, Fan T, Rubin DT. Dose escalation of biologics in biologic-naive patients with Crohn's disease: Outcomes from the ODESSA-CD study. J Manag Care Spec Pharm. 2024 Nov; 30(11):1276-1287.

View in: PubMed
Coats CJ, Masri A, Nassif ME, Barriales-Villa R, Arad M, Cardim N, Choudhury L, Claggett B, D?ngen HD, Garcia-Pavia P, Hag?ge AA, Januzzi JL, Lee MMY, Lewis GD, Ma CS, Maron MS, Miao ZM, Michels M, Olivotto I, Oreziak A, Owens AT, Spertus JA, Solomon SD, Tfelt-Hansen J, van Sinttruije M, Veselka J, Watkins H, Jacoby DL, German P, Heitner SB, Kupfer S, Lutz JD, Malik FI, Meng L, Wohltman A, Abraham TP. Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM. J Am Heart Assoc. 2024 Aug 06; 13(15):e035993.

View in: PubMed
Natov PS, Ivey-Miranda JB, Cox ZL, Rao VS, Butler J, Konstam MA, Kiernan MS, Kapur NK, Testani JM. Increased Spironolactone Dosing in Acute Heart Failure Alters Potassium Homeostasis but Does not Enhance Decongestion. J Card Fail. 2024 Nov; 30(11):1522-1526.

View in: PubMed
Karadkhelkar NM, Gupta P, Barasa L, Chilamakuri R, Hlordzi CK, Acharekar N, Agarwal S, Chen ZS, Yoganathan S. Chemical Derivatization Leads to the Discovery Of Novel Analogs of Azotochelin, a Natural Siderophore, as Promising Anticancer Agents. ChemMedChem. 2024 Jul 02; 19(13):e202300715.

View in: PubMed
Zaino AM, Dash RC, James SJ, MacGilvary N, Crompton A, McPherson KS, Stanzione M, Korzhnev DM, Dyson NJ, Chatterjee N, Cantor SB, Hadden MK. Lead compound profiling for small molecule inhibitors of the REV1-CT/RIR Translesion synthesis Protein-Protein interaction. Bioorg Med Chem. 2024 May 15; 106:117755.

View in: PubMed
Danzig CJ, Khanani AM, Kaiser PK, Chang MA, Kovach JL, Lally DR, Rachitskaya A, Sheth VS, Vajzovic L, Clark J, Tang J, Zhu L, Desai D, Chakravarthy U. Vision Loss Reduction with Avacincaptad Pegol for Geographic Atrophy: A 12-Month Post Hoc Analysis of the GATHER1 and GATHER2 Trials. Ophthalmol Retina. 2024 Nov; 8(11):1052-1060.

View in: PubMed
Masri A, Sherrid MV, Abraham TP, Choudhury L, Garcia-Pavia P, Kramer CM, Barriales-Villa R, Owens AT, Rader F, Nagueh SF, Olivotto I, Saberi S, Tower-Rader A, Wong TC, Coats CJ, Watkins H, Fifer MA, Solomon SD, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Meng L, Sohn RL, Wohltman A, Maron MS. Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4. J Card Fail. 2024 Nov; 30(11):1439-1448.

View in: PubMed

People

Explore

Similar Concepts

Top Journals